- NEuRoMS intervention and trial procedures were feasible and acceptable across three UK MS clinics, supporting progression to a definitive trial.
- High retention (>80%) and outcome completion (81% to 89%) demonstrated acceptability and reliable data collection at baseline, three and six months.
- Preliminary efficacy signal: 3.42-point improvement (effect size 0.48) on MS psychological impact; staffing-related recruitment challenges require addressing.
Mult Scler J Exp Transl Clin. 2026 Sep 24;12(3):20552173261487853. doi: 10.1177/20552173261487853. eCollection 2026 Jul-Sep.
ABSTRACT
BACKGROUND: Cognitive difficulties are common in people with multiple sclerosis (pwMS), yet access to neuropsychological rehabilitation is often limited or only provided to those with more severe impairments. The NEuRoMS intervention provides brief, tailored neuropsychological rehabilitation for pwMS with mild-to-moderate cognitive difficulties.
OBJECTIVES: To evaluate feasibility and acceptability of the intervention and test procedures for a definitive trial.
METHODS: A mixed-methods, multi-centre feasibility randomised controlled trial (RCT) was conducted. Feasibility outcomes were recruitment, retention, outcome completion, randomisation, intervention delivery and fidelity. Quantitative data were collected at baseline, 3- and 6-months, supplemented by interviews with pwMS and healthcare providers.
RESULTS: Seventy-nine participants were randomised (mean age = 54.5 (SD = 11.5); 70% women) from three UK MS clinics. Most feasibility criteria were met: retention (>80%) and outcome-measure completion (81%-89%) were high, and trial procedures were acceptable. Intervention delivery was feasible and delivered as intended, but staffing-related recruitment challenges need addressing in future trials. Preliminary signal of efficacy was observed, with 3.42-point difference (effect size = 0.48) in the planned primary outcome (MS psychological impact) favouring the intervention, supported by qualitative evidence of sustained behaviour change.
CONCLUSION: The NEuRoMS intervention and trial procedures were feasible and acceptable, with early indication of efficacy. A definitive RCT is underway.Trial registration: ISRCTN11203922; https://doi.org/10.1186/ISRCTN11203922.
PMID:43034528 | PMC:PMC13768670 | DOI:10.1177/20552173261487853
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

